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ox-LDLa b s t r a c t
CXCR2 plays a key role in protecting the integrity of the endothelium. Emerging evidence has
demonstrated that the long ncRNAs (lncRNA) Human metastasis associated lung adenocarcinoma
transcript 1 (MALAT1) participates in the regulation of the pathophysiological processes. However,
whether there is crosstalk between CXCR2 and MALAT1 remains unknown. In this study, we demon-
strated that MALAT1 was upregulated in patients with unstable angina. MALAT1 silencing signifi-
cantly downregulated the expression of the miR-22-3p target gene CXCR2 via reversing the effect
of the miR-22-3p, resulting in the aggravation of Oxidized low-density lipoprotein (ox-LDL)-
induced endothelial injury; this process was associated with the AKT pathway. Thus, MALAT1 pro-
tects the endothelium from ox-LDL-induced endothelial dysfunction partly through competing with
miR-22-3p for endogenous RNA.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Oxidized low-density lipoprotein (ox-LDL) has been widely
demonstrated to be involved in the development of atherosclerosis
by causing an oxidative chain reaction and inducing endothelial
dysfunction [1,2]. After binding to the lectin-like ox-LDL
receptor-1 on the endothelial cell surface, ox-LDL and its lipid con-
stituents induce reactive oxygen species (ROS) accumulation and
nitric oxide (NO) inhibition [2]. These factors contribute to the
destruction of the integrity of the endothelium and cause a series
of atherosclerosis-related diseases [3]. Moreover, ox-LDL induces
high expression of interleukin-8 in endothelial cells [4–6];
interleukin-8 is the ligand of the chemokine receptor CXCR2.
Numerous studies have demonstrated that CXCR2 has the abilityto promote cell proliferation, diminish cell apoptosis and enhance
angiogenesis [7,8], indicating that CXCR2 plays a key role in pro-
tecting the endothelium from ox-LDL-induced injury. However,
the regulation of the CXCR2-mediated protective effect on
endothelial cells remains elusive.
Genome-sequencing projects have demonstrated that more
than ninety percent of the genome is transcribed as non-coding
RNAs (ncRNAs). Only 2% of the human genome contains protein-
coding genes [9], indicating the need for a redefinition of the con-
cept of ncRNAs. ncRNAs include microRNAs (miRNAs), which con-
sist of 18–24 nucleotides, and long ncRNAs (lncRNAs), which are
longer than 200 nucleotides in length. Recently, accumulating evi-
dence has strongly implied that ncRNAs play a key role in regulat-
ing pathophysiological processes [10–12]. Human metastasis
associated lung adenocarcinoma transcript 1 (MALAT1; also
known as NEAT2), is an 8.7 kb lncRNA that maps to chromosome
11q13 and has been demonstrated to be overexpressed in several
cancers [13]. A previous study reported that MALAT1 promoted
aggressive renal cell carcinoma through Ezh2 [14]. MALAT1 silenc-
ing significantly suppresses the proliferation of esophageal squa-
mous cell carcinoma through the cell cycle at G2/M [15].
Furthermore, the high expression levels of conserved MALAT1 are
involved in the physiological progress of endothelial cells [16]
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study, we also found a marked increase in the expression of
MALAT1 in endothelial cells following 24 h of ox-LDL treatment.
However, little is known about the contribution of MALAT1 to
endothelial cell dysfunction.
lncRNAs may function as miRNAs ‘‘sponges” by interacting
through common response elements, resulting in the modulation
of the miRNA activity [18]. This crosstalk between lncRNAs and
miRNAs can be called the ‘competitive endogenous RNA (ceRNA)’
network. The ceRNA network is associated with lots of biological
processes, and the intervention of the interaction between lncRNAs
and miRNAs can be critical for biological development [10,14,15].
Because both the coding RNA CXCR2 and the non-coding RNA
MALAT1 have an effect on the integrity of the endothelium, we
hypothesed that MALAT1 post-transcriptionally regulated CXCR2
via ceRNA in response to ox-LDL-induced endothelial dysfunction.
Recent examples demonstrating that MALAT1‘‘sponges” miRNAs to
regulate specific target genes support this hypothesis [14,15]. Here,
we evaluated the possibility of crosstalk between CXCR2 and
MALAT1 and investigating whether the regulatory mechanism
was associated with the ceRNA network.2. Materials and methods
The experiments were conducted in accordance with the Decla-
ration of Helsinki and this study was approved by the ethics com-
mittee of the Xinhua Hospital School of Medicine, Shanghai
Jiaotong University.
2.1. Patient population and blood collection
A lot of 23 patients diagnosed with unstable angina (UA) by our
Division of Cardiology and 23 healthy subjects were recruited.
Their diagnoses were based on a history of chest pain, coronary
angiography results and characteristic ECG changes. The baseline
characteristics of the two groups were compared. A 10 ml sample
of peripheral blood was collected in an EDTA-containing vacu-
tainer tube from each individual for further analysis.
2.2. Cell culture
HUVECs were isolated from fresh human umbilical cords fol-
lowing the methods of a previous study [19]. Briefly, the separated
cord was placed in cord buffer containing NaCl (0.14 M), KCI
(0.004 M), phosphate buffer (0.001 M) and glucose (0.011 M). We
washed the blood out of the cord and added an appropriate
amount of 0.2% collagenase type II (Sigma) into the umbilical vein
for 15 min at 37 C. After incubation, the solution containing
HUVECs was rinsed into a centrifuge tube. After discarding the buf-
fer, the cells were cultured in DMEM high glucose medium con-
taining 20% fetal bovine serum at 37 C in a 5% CO2 incubator.
The entire process was performed under aseptic conditions within
3 h. Cells from passages three to five were used for this study.
2.3. Cell transfection
miR-22-3p mimics and inhibitors (Dharmacon, 50 nM) were
used to upregulate or downregulate the miR-22-3p expression.
Cells were transfected with the CXCR2-siRNA (Ribobio), MALAT1-
shRNA (Hanbio), or miR-22-3p mimics, inhibitors or controls
(Dharmacon) using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions. Changes in RNA expression were
determined by qRT-PCR 24 h after transfection, and changes in
protein expression were measured by Western blotting 48 h after
transfection.2.4. RNA preparation, RT and qPCR
Total RNA was extracted using the Trizol reagent (Invitrogen)
following the manufacturer’s protocol. Next, the Primer-ScriptTM
one step RT-PCR kit (TaKaRa) was used for the reverse transcrip-
tion of mRNAs and lncRNAs, and the miRcute miRNA cDNA kit
(Tiangen) was used for the reverse transcription of miRNAs. The
SYBR kit (TaKaRa) was used for detection in the ABI7500 system
(Applied Biosystems). b-Actin was used as the endogenous control
for mRNAs and lncRNAs, and U6 was used as the endogenous con-
trol for miRNAs. The relative expression levels among groups were
calculated by the 2DDCt method. The following primers were used:
CXCR2 F: 50-CCGTTTTCTCCTTCCTGGGT-30, and R: 50-GCTGTGA
CCTGCTGTTATTGG-30; MALAT1: F: 50-ATGCGAGTTGTTCTCCGTCT-
30, and R: 50-TATCTGCGGTTTCCTCAAGC-30; b-actin: F: 50-AGAGCC
TCGCCTTTGCCGAT-30, and R: 50-TGCCAGATTTTCTCCATGTCGT-30;
miR-22-3p: 50-AAGCTGCCAGTTGAAGAACTGT-30; U6: 50- CGCTTC
GGCAGCACATATACTAAAATTGGAAC-30.
2.5. Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay Kits (Elabscience) were
used to detect interleukin-1or interleukin-8 in cell culture super-
natants following 24 h of ox-LDL treatment.
2.6. RNA immunoprecipitation assay (RIP)
The Magna RIP RNA-Binding Protein Immunoprecipitation Kit
(Millipore) was used according to the manufacturer’s protocol to
analyze whether MALAT1 was associated with the RISC complex.
IgG (Millipore) was used as the negative control and anti-
snRNP70 as the positive control (Millipore).
2.7. Western blotting (WB)
Primary antibodies targeting Ago2 (1:1000 dilution; Millipore),
CXCR2 (1:1000 dilution; Cell Signaling), p-AKT, AKT (1:1000 dilu-
tion; Cell Signaling), and cleaved Casp3 (1:1000 dilution; Cell Sig-
naling) were used. The antibody for b-actin (1:1000 dilution;
Beyotime) was used as the endogenous control. The assay was per-
formed as follows. HUVECs were lysed for 1.5 h on ice by a cell lysis
solution containing 1% phenylmethanesulfonyl fluoride buffer.
Then 12% SDS–PAGE gels (Millipore) were used for equal protein
loading (50 lg) electrophoresis. The gels were run under the same
experimental conditions.
2.8. Flow cytometric analysis
The apoptosis of HUVECs induced by ox-LDL was assessed using
a FITC Annexin V Apoptosis Detection Kit I (BD) following the man-
ufacturer’s protocol. In brief, the cells were washed with cold PBS
and resuspended at a density of 1  106 cells/ml using 1 Binding
Buffer. Then, 5 ll of FITC Annexin V and 5 ll propidium iodide
were added to the resuspended cells for 15 min at room tempera-
ture in the dark. The cells were analyzed with a Beckman Coulter
FC500 (Beckman) within 1 h.
2.9. Capillary-like structure formation assay
An in vitro endothelial tube formation assay was performed to
study the modulation of angiogenesis by miR-22-3p, CXCR2 or
MALAT1 as described previously [20]. Briefly, 104 endothelial cells
pretreated with miR-22-3p, CXCR2-siRNA or MALAT1-shRNA for
24 h were seeded into a Matrigel-coated 96-well plate. Following
6 h of incubation at 37 C, pictures were taken using a fluorescent
microscope. Each assay was repeated five times.
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A total of 106 endothelial cells were seeded into a six-well plate
and incubated at 37 Cuntil 60% confluent. Then, the cellswere trea-
ted with miR-22-3p, CXCR2-siRNA or MALAT1-shRNA for another
24 h, and the migration distance was observed by microscope.
2.11. Luciferase activity assay
The 30-UTR fragment of CXCR2, which contains the predicted
potential miRNA binding sites, was amplified by PCR using theFig. 1. The interaction among MALAT1, CXCR2 and miR-22-3p. (A) The inhibitory effe
transfecting MALAT1-shRNA1 into ECs for 24 h, the expression levels of miR-22-3p (B) a
siRNA on the CXCR2 mRNA level was detected by RT-PCR. The expression of MALAT1 (E)
Changes in EC miR-22-3p levels 24 h after transfection with the vehicle, the miR-22-3p
expression levels of MALAT1 (H) and CXCR2 (I) were measured in response to the miR-following primers: F: 50-GGCGGCTCGAGACGTTCTTACTAGTTT-30,
and R: 50-AATGCGGCCGCAGTAAAAATGGTTT-30. The mutant was
constructed by introducing point mutations into the seed binding
site for miR-22-3p using the following primers: F: 50-AAGACAG
TATCCGAGCT-30 and R: 50-AGCTCGGATACTGTCTT-30. The wild
type and mutant fragments were subcloned into the pmiR-
RB-REPORTTM vector (Ribobio). The vectors and miRNA mimics
were co-transfected into HUVECs for 24 h and the luciferase
activity was subsequently tested. Similarly, either the wild type
or mutant 30-UTR of AKT or the fragment of MALAT1 containing
the predicted miR-22-3p targeting site (chr11:65270634–6527065ct of MALAT1-shRNA on the MALAT1 mRNA level was detected by RT-PCR. After
nd CXCR2 (C) were measured by RT-PCR or WB. (D) The inhibitory effect of CXCR2-
and miR-22-3p (F) were measured following 24 h of CXCR2-siRNA3 treatment. (G)
mimics, the mimic control, the miR-22-3p inhibitors or the inhibitor control. The
22-3p mimics or the miR-22-3p inhibitors. NS not significant, *p < 0.05.
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above.
2.12. Statistics
The SPSS 18 software (SPSS Inc., USA) was used for statistical
analysis. The data are presented as the mean ± standard error.
The expression differences between two groups were tested using
a paired samples t-test. A P-value <0.05 was considered statisti-
cally significant.
3. Results
3.1. The relationship among MALAT1, miR-22-3p and CXCR2
Several publicly available bioinformatics web sites [Starbase
v2.0 (http://starbase.sysu.edu.cn/mirLncRNA.php) and TargetScan
(http://www.targetscan.org/)] showed that there were six poten-
tial miRNAs with complementary base pairing with both MALAT1
and CXCR2 (Supplementary Fig. 1A): miR-1, miR-22-3p, miR-23a,
miR-23b, miR-23c, and miR-376. The MALAT1-shRNA obviously
decreased the expression of MALAT1 (approximately 60% reduc-
tion, Fig. 1A). Following 24 h of MALAT1 silencing treatment, the
expression of miR-22-3p showed the biggest change (increased
approximately 2.5-fold) among the six potential miRNAs (Fig. 1B,
Supplementary Fig. 1B). By contrast, the protein expression of
CXCR2 was downregulated at 48 h after transfection (approxi-
mately 50% reduction, Fig. 1C).Fig. 2. MALAT1 and miR-22-3p expression in UA patients and ox-LDL treated ECs. The
(n = 23) and patients with UA (n = 23) were measured by RT-PCR. Following 24 h of treat
ml) for different times (D), the mRNA expression of MALAT1, miR-22-3p and CXCR2 weAlthough the CXCR2-siRNA3 significantly decreased the expres-
sion of CXCR2 (approximately 60% reduction, Fig. 1D), no expression
changes were found in MALAT1 and miR-22-3p in response to
CXCR2 silencing (Fig. 1E and F). By contrast, the expression of both
MALAT1 and CXCR2 was significantly reduced in response to the
miR-22-3p mimics and increased after transfection with the miR-
22-3p inhibitors (Fig. 1H and I). These data suggest that a potential
link may exist among the lncRNA MALAT1, miR-22-3p and CXCR2.
3.2. Changes in MALAT1 and miR-22-3p expression in UA patients and
ox-LDL treated ECs
The expression levels of the lncRNA MALAT1 and miR-22-3p
were measured in the plasma obtained from 23 patients with UA
and 23 healthy subjects. There were no significant differences in
the baseline characteristics of the two groups (Supplementary
Table 1). The expression of MALAT1 was upregulated (Fig. 2A)
and miR-22-3p was downregulated (Fig. 2B) in patients with UA.
Following 24 h of ox-LDL (0, 30, 50, 100, and 150 lg/ml) treatment,
the expression of MALAT1 and CXCR2 in the ECs was increased and
the expression of miR-22-3p was decreased with the increasing ox-
LDL concentration in a dose- dependent manner (Fig. 2C). Further-
more, the expression of MALAT1, CXCR2 and miR-22-3p showed a
similar trend over time (Fig. 2D).
3.3. Direct binding between miR-22-3p and MALAT1
The lncRNA MALAT1 shares a miRNA response element with
miR-22-3p. The luciferase assay revealed that the miR-22-3p mim-levels of circulating lncRNA MALAT1 (A) and miR-22-3p (B) in healthy volunteers
ment with several concentrations of ox-LDL (C), or treatment with ox-LDL (100 lg/
re measured by RT-PCR. *p < 0.05.
Fig. 3. The potential mechanism of the negative regulation of miR-22-3p by MALAT1. (A) The wild type and mutated miR-22-3p binding sites in the MALAT1 30-UTR were
shown in the upper panel. The miR-22-3p mimics and the luciferase constructs were co-transfected into endothelial cells. The negative control was used as a reference.
Cellular lysates from ECs were used for RIP with an Ago2 antibody. The Ago2 protein level was detected by WB (B), and the mRNA expression of MALAT1 (C) and miR-22-3p
(D) in the immunoprecipitate was measured by RT-PCR. Wt wild type, Mut mutant, NC negative control, M miR-22-3p mimics, *p < 0.05.
Fig. 4. MALAT1 protects endothelial cells through the miR-22-3p/CXCR2 axis. (A) The wild type and mutated miR-22-3p binding sites in the 30-UTR of CXCR2 were shown in
the upper panel. The miR-22-3p mimics and the luciferase constructs were co-transfected into endothelial cells. The negative control was used as a reference. (B) The protein
expression level of CXCR2 was measured in the absence of miR-22-3p or MALAT1 by WB. (C) The apoptotic effects of miR-22-3p, MALAT1 and CXCR2 on ECs were revealed by
flow cytometry analysis. The capillary tube formation and the migration effects of miR-22-3p (D), MALAT1 and CXCR2 on ECs were also detected. *p < 0.05.
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reduced effect was found for the MALAT1mutant (Fig. 3A). miRNAs
function through the formation of RNA-induced silencing complex
(RISC), of which the Argonaute protein 2 (Ago2) is the key compo-
nent [21]. We subsequently performed an RIP experiment to inves-
tigate whether MALAT1 and miR-22-3p were in the RISC complex.
The Ago2 antibody was able to precipitate the Ago2 protein from
the digested cells (Fig. 3B). The mRNA expression levels of both
MALAT1 and miR-22-3p were obviously enriched in the immuno-
precipitates (approximately 48-fold and 42-fold, respectively
Fig. 3C and D). This result suggests that direct binding exists
between MALAT1 and miR-22-3p.
3.4. MALAT1 protects endothelial cells through the miR-22-3p/CXCR2
axis
miR-22-3p is a tumor-suppressive miRNA that suppresses cell
proliferation and promotes apoptosis in cancers [22,23]. To inves-
tigate whether CXCR2 is a direct target of miR-22-3p, the 30-UTR ofFig. 5. MALAT1/miR-22-3p/CXCR2 signaling is associated with the AKT pathway. (A) The
IL-8 expression in response to MALAT1 silencing. (C) After 48 h of IL-8 (50 ng/ml) or CX
WB. (D) The wild type and mutated miR-22-3p binding sites in the 30-UTR of AKT1 were s
co-transfected into endothelial cells. The negative control was used as a reference. (E) Th
(F) After 48 h of MALAT1-shRNA1 or miR-22-3p inhibitors treatment, the protein levels of
control, Con control, M miR-22-3p mimics, *p < 0.05.CXCR2 was cloned into a luciferase reporter plasmid. The wild type
showed significantly reduced expression in the presence of miR-
22-3p, whereas no suppression of activity was observed for the
mutant (Fig. 4A). We subsequently assessed CXCR2 protein levels
after transfection of the miR-22-3p inhibitors or MALAT1-
shRNA1 into endothelial cells and found that the decreased expres-
sion of CXCR2 in response to MALAT1-shRNA1 could be blocked by
miR-22-3p knockdown (Fig. 4B).
CXCR2, which is the target gene of miR-22-3p, is involved in
protecting endothelial cells from ox-LDL-induced injury [7,8]. The
flow cytometric analysis revealed that the overexpression of
miR-22-3p significantly increased EC apoptosis by approximately
25%. Moreover, the decreased percentage of apoptotic cells due
to miR-22-3p knockdown was offset by transfection with CXCR2-
siRNA3 or MALAT1-shRNA1 (Fig. 4C). Because CXCR2 is also asso-
ciated with the process of angiogenesis, we subsequently mea-
sured the migration and angiogenesis effect of endothelial cells.
The migration and angiogenesis inhibition effects of the CXCR2-
siRNA3 and MALAT1-shRNA1 were attenuated by the miR-22-3prelationship among the cell count and the CXCR2 ligands. (B) Changes in the IL-1 and
CR2-siRNA treatment, the protein levels of p-AKT, AKT and Casp3 were detected by
hown in the upper panel. The miR-22-3p mimics and the luciferase constructs were
e protein levels of p-AKT, AKT and Casp3 were modulated by the miR-22-3p mimics.
p-AKT, AKT and Casp3 were detected byWB.Wtwild type,Mutmutant, NC negative
Fig. 6. The mechanism schematic. Extracellular deposition of ox-LDL induces high
expression of MALAT1. Then, MALAT1 ‘‘sponges” miR-22-3p to upregulate the
target genes CXCR2 and AKT. Finally, high expression of CXCR2 resists ox-LDL-
induced endothelial cells dysfunction via the AKT pathway.
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endothelial cells partly via competing with miR-22-3p, which
results in the upregulation of CXCR2.
3.5. MALAT1/miR-22-3p/CXCR2 signaling is involved in the AKT
pathway
Previous results have demonstrated that IL-1 and IL-8 modulate
the functions of endothelial cells through the CXCR2/AKT pathway
[5,6,20,24]. There was an inverse relationship between the quan-
tity of live cells and IL-1/IL-8 following treatment with different
concentrations of ox-LDL (Fig. 5A). Furthermore, MALAT1 inhibi-
tion attenuated the expression of IL-1/IL-8 in the ox-LDL treated
ECs (Fig. 5B). These results indicate that CXCR2 plays a key role
in protecting the endothelium from ox-LDL-induced injury.
Although the total AKT protein level was unaffected in response
to IL-8 treatment, the phosphorylation of AKT was increased. This
phenomenon disappeared after co-transfection with CXCR2-
siRNA3 (Fig. 5C). Interestingly, AKT1 is also a target gene of miR-
22-3p (Fig. 5D). The overexpression of miR-22-3p significantly
decreased the AKT protein level (Fig. 5E). Furthermore, the
decreased expression of AKT in response to MALAT1 silencing
could be offset by the miR-22-3p inhibitors (Fig. 5F). Taken
together, our results suggested that the AKT pathway might be
downstream of MALAT1/miR-22-3p/CXCR2 signaling during the
protection of endothelial cells from ox-LDL.4. Discussion
Ox-LDL and a large number of inflammatory cytokines (i.e., the
CXC chemokine family) are associated with the progression of
atherosclerosis [25,26]. The deposition of ox-LDL in the endothelial
barrier is an important early step in atherosclerosis [25]. Previous
results have suggested that ox-LDL might promote atherosclerosis
through the upregulation of CXCR2, which is a G protein-coupled
receptor for chemokines [27,28]. However, other reports demon-
strated that CXCR2 protected the endothelial barrier against injury
by inflammatory factors during the early stage of atherosclerosis
[7,8]. These reports indicate that CXCR2 may play different roles
during the different stages of atherosclerosis. Therefore, it is neces-
sary to understand the mechanism underlying the CXCR2-induced
regulation.
Recently, lots of studies have advocated the important role that
lncRNAs play in the regulation of gene expression. For examples,
lncRNA CCAT1 levels are significantly higher in colorectal cancer
[29] and promote gallbladder cancer development via negative
modulation of miRNA-218-5p [10]. HOTAIR is also overexpressed
in several cancers and is associated with their differentiation and
aggressiveness through competition with miRNAs [30–32].
Although emerging evidence suggests that the lncRNAs participate
in the progression of cancers, the roles lncRNAs play in cardiovas-
cular diseases are poorly understood. One study noted that
lincRNA-p21 might act as a novel regulator of vascular smooth
muscle cell proliferation and promote neointima formation [33].
A similar report suggested that the lncRNA APF plays a key role
in the regulation of autophagic cell death and myocardial infarc-
tion via targeting miR-188-3p [34]. Therefore, investigations
regarding the crosstalk between lncRNAs and miRNAs could dee-
pen our understanding of the mechanisms underlying cardiovascu-
lar diseases, which are the most prominent causes of death
worldwide.
The well-conserved lncRNA MALAT1 is not only upregulated in
a variety of tumors [13–15,35] but also highly expressed in
endothelial cells [16]. Although MALAT1 functions in multiple
pathways [14,36,37], the ceRNA hypothesis provides new insightinto gene regulation. Previous results have shown that several
miRNAs, such as miR-101, miR-217, miR-125b and miR-9, were
negatively correlated with MALAT1 [15,35,38]. The binding of miR-
NAs to MALAT1 decreases miRNA levels and is accompanied by
increases in the expression of miRNA target genes [39,40]. This
finding indicates that MALAT1 acts as a sponge for different miR-
NAs in a cell-type dependent manner. However, the crosstalk
between involving MALAT1, CXCR2 and miRNAs with respect to
ox-LDL-induced endothelial dysfunction remains unknown. Here,
we observed that the MALAT1/miR-22-3p/CXCR2 signaling path-
way protected endothelial cells from ox-LDL-induced endothelial
dysfunction in the setting of atherosclerosis.
In this study, the interaction among the lncRNAMALAT1, CXCR2
and miR-22-3p suggested that a potential link might exist among
them. We demonstrated that the expression of MALAT1 and
miR-22-3p among patients with UA was consistent with their
expression changes in endothelial cells following 24 h of ox-LDL
treatment. Subsequently, luciferase assay and RIP experiments
showed that direct binding existed between MALAT1 and
miR-22-3p. Moreover, the miR-22-3p binding site was indispens-
able for the attenuation of endothelial dysfunction by MALAT1.
These findings suggested that MALAT1 modulated the expression
of CXCR2, at least in part, by competing with miR-22-3p.
Although emerging examples of ceRNA have been reported,
many questions still need to be answered. One of the key consider-
ations concerning the crosstalk between lncRNAs and miRNAs is
their abundance. The expression levels of both the lncRNAs and
miRNAs would affect the ceRNA effectiveness [41]. lncRNAs with
a low abundance have a limited inhibitory effect on specific miR-
NAs. Similarly, the regulatory effects would not be affected if the
miRNAs shared a low expression level in the cells [42]. Therefore,
in this study, we focused on the well-conserved lncRNA MALAT1,
which is highly expressed in endothelial cells [16]. Our results sug-
gested the possibility of a ceRNA mechanism in endothelial cells.
Another important concern is the crosstalk levels. Hundreds of tar-
get genes could be regulated by one miRNA, and one lncRNA may
‘‘sponge” multiple miRNAs [43,18]. Thus, mechanism behind
ceRNA is not a single-strand contact but rather a largely unknown
network mode. Although more research needs to be done, the find-
ings in our study may inspire future atherosclerosis research.
3196 Y. Tang et al. / FEBS Letters 589 (2015) 3189–3196In summary, our study demonstrates the interactions among
the lncRNA MALAT1, miR-22-3p and CXCR2 in ox-LDL-induced
endothelial dysfunction. MALAT1 protects the endothelial barrier
from injury via inhibiting the expression of miR-22-3p and upreg-
ulating the expression of CXCR2, which is associated with the AKT
pathway (Fig. 6). These results may provide new insight for the
prevention and cure of atherosclerosis disease.
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